The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Open accessAbstract
Summary: The remarkable success of immune therapies emphasizes the need for immune‐competent cancer models. Elegant genetically engineered mouse models of a variety of cancers have been established, but their effective use is limited by cost and difficulties in rapidly generating experimental data. Some mouse cancer cell lines are transplantable to immunocompetent host mice and have been utilized extensively to study cancer immunology. Here, we describe the Yale University Mouse Melanoma (YUMM) lines, a comprehensive system of mouse melanoma cell lines that are syngeneic to C57 BL/6, have well‐defined human‐relevant driver mutations, and are genomically stable. This will be a useful tool for the study of tumor immunology and genotype‐specific cancer biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citationRetractedCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Cancer cell lines have also been utilized to evaluate the response of the immune system to cancer (Gubin et al., 2014).”
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
Self-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citationTherapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M. C., Wiesner, T., Rosen, N., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 494
Self-citationβ-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas
Damsky, W. E., Curley, D. P., Santhanakrishnan, M., Rosenbaum, L. E., Platt, J. T., Gould Rothberg, B. E., Taketo, M. M., Dankort, D., Rimm, D. L., McMahon, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.030 · Cited by 351
Self-citationWard, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
Liu, M., Sakamaki, T., Casimiro, M. C., Willmarth, N. E., Quong, A. A., Ju, X., Ojeifo, J., Jiao, X., Yeow, W.-S., Katiyar, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0732 · Cited by 227
Semenza, G. L. (2013) · Oncogene · doi:10.1038/onc.2012.578 · Cited by 201
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.014 · Cited by 142
Self-citationIsolation and Molecular Characterization of Circulating Melanoma Cells
Luo, X., Mitra, D., Sullivan, R. J., Wittner, B. S., Kimura, A. M., Pan, S., Hoang, M. P., Brannigan, B. W., Lawrence, D. P., Flaherty, K. T., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.039 · Cited by 119
Self-citationBlocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
Bertrand, F., Rochotte, J., Colacios, C., Montfort, A., Tilkin-Mariamé, A.-F., Touriol, C., Rochaix, P., Lajoie-Mazenc, I., Andrieu-Abadie, N., Levade, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2524 · Cited by 113 · cited 2×
“The YUMM lines have been utilized by numerous investigators prior to this initial description (Bertrand et al., 2015; Scortegagna et al., 2015; Ho et al., 2015; Obenauf et al., 2015; Cintolo et al., 2016; Kaur and Marchbank et al., 2016).”
MethodCooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108 · cited 1×
“We and others have generated several additional GEMMs based on additional specific genetic alterations relevant to melanoma biology (Damsky et al., 2011; Damsky et al., 2015; Dankort et al., 2009; Nogueira et al., 2010; Scortegagna et al., 2014; VanBrocklin et al., 2010).”
BackgroundSelf-citationMultiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032
Jenkins, M. H., Steinberg, S. M., Alexander, M. P., Fisher, J. L., Ernstoff, M. S., Turk, M. J., Mullins, D. W., & Brinckerhoff, C. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12220 · Cited by 93
Immunization against endogenous retroviral tumor-associated antigens.
Kershaw, M. H., Hsu, C., Mondesire, W. H., Parker, L. L., Wang, G., Overwijk, W. W., Lapointe, R., Yang, J. C.-H., Wang, R., Restifo, N. P., et al. (2001) · PubMed · Cited by 84
Scortegagna, M., Ruller, C. M., Feng, Y., Lazova, R. Z., Kluger, H., Li, J., De, S. K., Rickert, R. C., Pellecchia, M., Bosenberg, M., et al. (2013) · Oncogene · doi:10.1038/onc.2013.383 · Cited by 81
Self-citationCRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Fragomeni, R. A. S., Chung, H. W., Landesman, Y., Senapedis, W. T., Saint‐Martin, J., Tsao, H., Flaherty, K. T., Shacham, S., Kauffman, M. G., & Cusack, J. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1171 · Cited by 66
Scortegagna, M., Lau, E. K., Zhang, T., Feng, Y., Sereduk, C., Yin, H. H., De, S. K., Meeth, K. M., Platt, J. T., Langdon, C. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2785 · Cited by 61
Self-citationSequence and Insertion Sites of Murine Melanoma-Associated Retrovirus
Li, M., Huang, X., Zhu, Z., & Gorelik, E. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9178-9186.1999 · Cited by 54
VanBrocklin, M. W., Robinson, J. P., Lastwika, K. J., Khoury, J. D., & Holmen, S. L. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00717.x · Cited by 38
The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
Jenkins, M. H., Croteau, W., Mullins, D. W., & Brinckerhoff, C. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.007 · Cited by 37
Cintolo-Gonzalez, J., Datta, J., Xu, S., Gupta, M., Somasundaram, R., & Czerniecki, B. J. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000203 · Cited by 15
de Jel, M. M., Engelmann, J. C., Kunz, M., Schiffner, S., Kuphal, S., & Bosserhoff, A. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12244 · Cited by 5
Cited by
Lymph protects metastasizing melanoma cells from ferroptosis
Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., Gu, Z., McCormick, M. L., Durham, A. B., Spitz, D. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2623-z · Cited by 896
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 672
Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion
Yu, Y.-R., Imrichova, H., Wang, H., Chao, T., Xiao, Z., Gao, M., Rincon-Restrepo, M., Franco, F., Genolet, R., Cheng, W.-C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0793-3 · Cited by 593
Metabolic heterogeneity confers differences in melanoma metastatic potential
Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J. M., Shen, B., Solmonson, A., Murphy, M. M., Gu, Z., Gu, W., Martin, M., et al. (2020) · Nature · doi:10.1038/s41586-019-1847-2 · Cited by 509
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
Metadata
- Authors
- Meeth, K., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. W.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2016-08-03
- Volume
- 29
- Issue
- 5
- Pages
- 590-597
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2417761579
- Cited by
- 318
- References
- 24
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.